Submitted:
26 June 2025
Posted:
30 June 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results and Discussions
3. Materials and Methods
3.1. Peritumoral Tissue
3.2. Extraction and Purification of Gangliosides
3.3. Ion Mobility Mass Spectrometry
3.4. Ganglioside Abbreviation, Nomenclature and Assignment of the Mass Spectra
4. Conclusions
Acknowledgments
References
- Lang, M.; Colby, S.; Ashby-Padial, C.; Bapna, M.; Jaimes, C.; Rincon, S.P.; Buch, K. An imaging review of the hippocampus and its common pathologies. J. Neuroimaging 2023, 34, 5–25. [CrossRef]
- Madhusoodanan, S.; Ting, M.B.; Farah, T.; Ugur, U. Psychiatric aspects of brain tumors: A review. World J. Psychiatry 2015, 5, 273–285. [CrossRef]
- Realmuto, S.; Cinturino, A.; Arnao, V.; Mazzola, M.A.; Cupidi, C.; Aridon, P.; Ragonese, P.; Savettieri, G.; D'Amelio, M. Tumor diagnosis preceding Alzheimer's disease onset: is there a link between cancer and Alzheimer's disease?J. Alzheimers Dis.2012, 31, 177–182.
- Lanni, C.; Masi, M.; Racchi, M.; Govoni, S. Cancer and Alzheimer’s disease inverse relationship: an age-associated diverging derailment of shared pathways. Mol. Psychiatry 2020, 26, 280–295. [CrossRef]
- Xia, S.; Chen, H.; Tang, T. Risk of death from Alzheimer's disease associated with brain tumor, glioma, and glioblastoma. J. Alzheimers Dis.2023, 96, 623–631.
- Ahmad, M.H.; Rizvi, M.A.; Ali, M.; Mondal, A.C. Neurobiology of depression in Parkinson’s disease: Insights into epidemiology, molecular mechanisms and treatment strategies. Ageing Res. Rev.2023, 85, 101840.
- Bondar, L.I.; Osser, B.; Miuța, C.C.; Petran, D.; Baltean, A.I.; Butari, D.B.; Mariș, M.A.; Piroș, L.E.; Almășan, R.; Gavrila-Ardelean, M.; et al. Gender-Specific Insights into Depression in Patients with Ischemic Heart Disease: Findings from a Pilot Study Using a Self-Developed Questionnaire. Diseases 2024, 12, 320. [CrossRef]
- Bondar, L.I.; Iovanovici, D.C.; Măduța, V.; Butari, D.B.; Șandor, F.M.; Mariș, M.A.; Piroș, L.E.; Miuța, C.C.; Toderescu, C.D.; Popescu, M.I. Screening Depression in Ischemic Heart Disease: Gender Differences and Psychosocial Implications Using a Self-Developed Questionnaire. J. Clin. Med. 2025, 14, 837. [CrossRef]
- Battat, M.; Omair, N.; WildAli, M.A.; Alkaissi, A.; Amer, R.; Koni, A.A.; Salameh, H.T.; Zyoud, S.H. Assessment of depression symptoms among cancer patients: a cross-sectional study from a developing country. Sci. Rep. 2024, 14, 11934. [CrossRef]
- Starkweather, A.R.; Sherwood, P.; Lyon, D.E.; McCain, N.L.; Bovbjerg, D.H.; Broaddus, W.C. A Biobehavioral Perspective on Depressive Symptoms in Patients With Cerebral Astrocytoma. J. Neurosci. Nurs. 2011, 43, 17–28. [CrossRef]
- Alshoabi, S.A.; Alareqi, A.A.; Omer, A.M.; Suliman, A.G.; Daqqaq, T.S. Diffuse astrocytoma and the diagnostic dilemma of an unusual phenotype: A case report. Radiol. Case Rep. 2020, 16, 319–326. [CrossRef]
- Kim, M.M.; Parolia, A.; Dunphy, M.P.; Venneti, S. Non-invasive metabolic imaging of brain tumours in the era of precision medicine. Nat. Rev. Clin. Oncol. 2016, 13, 725–739. [CrossRef]
- Tonn, J.C.; Teske, N.; Karschnia, P. Astrocytomas of the spinal cord. Neurooncol. Adv.2024, 6, 48–56.
- Khandwala, K.; Mubarak, F.; Minhas, K. The many faces of glioblastoma: Pictorial review of atypical imaging features. Neuroradiol. J. 2020, 34, 33–41. [CrossRef]
- Weller, M.; van den Bent, M.; Hopkins, K.; Tonn, J.C.; Stupp, R.; Falini, A.; Cohen-Jonathan-Moyal, E.; Frappaz, D.; Henriksson, R.; Balana, C.; et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014, 15, e395–e403. [CrossRef]
- Camelo-Piragua, S.; Jansen, M.; Ganguly, A.; Kim, J.C.; Louis, D.N.; Nutt, C.L. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol. 2010, 119, 509–511. [CrossRef]
- Brennan, P.M.; Butler, H.J.; Christie, L.; Hegarty, M.G.; Jenkinson, M.D.; Keerie, C.; Norrie, J.; O’bRien, R.; Palmer, D.S.; Smith, B.R.; et al. Early diagnosis of brain tumours using a novel spectroscopic liquid biopsy. Brain Commun. 2021, 3, fcab056. [CrossRef]
- Grishin, A.; Achkasova, K.; Kukhnina, L.; Sharova, V.; Ostapyuk, M.; Yashin, K. Peritumoral Brain Zone in Astrocytoma: Morphology, Molecular Aspects, and Clinical Manifestations (Review). Sovrem. Teh. v Med. 2024, 16, 79–88. [CrossRef]
- Sarbu, M.; Petrica, L.; Clemmer, D.E.; Vukelić, Ž.; Zamfir, A.D. Gangliosides of Human Glioblastoma Multiforme: A Comprehensive Mapping and Structural Analysis by Ion Mobility Tandem Mass Spectrometry. J. Am. Soc. Mass Spectrom. 2021, 32, 1249–1257. [CrossRef]
- Zamfir, A.D.; Fabris, D.; Capitan, F.; Munteanu, C.; Vukelić, Ž.; Flangea, C. Profiling and sequence analysis of gangliosides in human astrocytoma by high-resolution mass spectrometry. Anal. Bioanal. Chem. 2013, 405, 7321–7335. [CrossRef]
- Sarbu, M.; Fabris, D.; Vukelić, Ž.; Clemmer, D.E.; Zamfir, A.D. Ion Mobility Mass Spectrometry Reveals Rare Sialylated Glycosphingolipid Structures in Human Cerebrospinal Fluid. Molecules 2022, 27, 743. [CrossRef]
- Sarbu, M.; Ica, R.; Sharon, E.; Clemmer, D.E.; Zamfir, A.D. Glycomics by ion mobility tandem mass spectrometry of chondroitin sulfate disaccharide domain in biglycan. J. Mass Spectrom. 2023, 58, e4908. [CrossRef]
- Biricioiu, M.R.; Sarbu, M.; Ica, R.; Vukelić, Ž.; Kalanj-Bognar, S.; Zamfir, A.D. Advances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers. Int. J. Mol. Sci. 2024, 25, 1335. [CrossRef]
- Sarbu, M.; Vukelić, Ž.; Clemmer, D.E.; Zamfir, A.D. Ion mobility mass spectrometry provides novel insights into the expression and structure of gangliosides in the normal adult human hippocampus. Anal. 2018, 143, 5234–5246. [CrossRef]
- Nazha, B.; Inal, C.; Owonikoko, T.K. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Front. Oncol. 2020, 10, 1000. [CrossRef]
- Cavdarli, S.; Groux-Degroote, S.; Delannoy, P. Gangliosides: The Double-Edge Sword of Neuro-Ectodermal Derived Tumors. Biomolecules 2019, 9, 311. [CrossRef]
- Groux-Degroote, S.; Delannoy, P. Cancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy. Int. J. Mol. Sci. 2021, 22, 6145. [CrossRef]
- Shi, M.; Nan, X.-R.; Liu, B.-Q. The Multifaceted Role of FUT8 in Tumorigenesis: From Pathways to Potential Clinical Applications. Int. J. Mol. Sci. 2024, 25, 1068. [CrossRef]
- Svennerholm, L.; Fredman, P. A procedure for the quantitative isolation of brain gangliosides. Biochim. et Biophys. Acta (BBA) - Lipids Lipid Metab. 1980, 617, 97–109. [CrossRef]
- Vukelic, Z.; Metelmann, W.; Müthing, J.; Kos, M.; Peter-Katalinic, J. Anencephaly: Structural Characterization of Gangliosides in Defined Brain Regions. Biol. Chem. 2001, 382, 259–74. [CrossRef]
- Vukelić, Ž.; Kalanj-Bognar, S.; Froesch, M.; Bîndilă, L.; Radić, B.; Allen, M.; Peter-Katalinić, J.; Zamfir, A.D. Human gliosarcoma-associated ganglioside composition is complex and distinctive as evidenced by high-performance mass spectrometric determination and structural characterization. Glycobiology 2007, 17, 504–515. [CrossRef]
- Schiopu, C.; Flangea, C.; Capitan, F.; Serb, A.; Vukelić, Ž.; Kalanj-Bognar, S.; Sisu, E.; Przybylski, M.; Zamfir, A.D. Determination of ganglioside composition and structure in human brain hemangioma by chip-based nanoelectrospray ionization tandem mass spectrometry. Anal. Bioanal. Chem. 2009, 395, 2465–2477. [CrossRef]
- Schiopu, C.; Vukelić, Ž.; Capitan, F.; Kalanj-Bognar, S.; Sisu, E.; Zamfir, A.D. Chip-nanoelectrospray quadrupole time-of-flight tandem mass spectrometry of meningioma gangliosides: A preliminary study. Electrophoresis 2012, 33, 1778–1786. [CrossRef]
- Svennerholm, L. Ganglioside Designation. In Structure and Function of Gangliosides; Springer: Boston, MA, USA, 1980; Volume 125, p. 11. [CrossRef]
- Chester, M. IUPAC-IUB joint commission on biochemical nomenclature (JCBN) nomenclature of glycolipids. J. Mol. Biol. 1999, 286, 963–970. [CrossRef]
- Domon, B.; Costello, C.E. A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. Glycoconj. J. 1988, 5, 397–409. [CrossRef]
- Costello, C.E.; Juhasz, P.; Perreault, H. New mass spectral approaches to ganglioside structure determinations. Prog. Brain Res.1994, 101, 45–61.
- Ann, Q.; Adams, J. Structure determination of ceramides and neutral glycosphingolipids by collisional activation of [M + Li]+ ions. J. Am. Soc. Mass Spectrom. 1992, 3, 260–263. [CrossRef]






| No | m/z exp | m/z theor | Mass accuracy (ppm) | Proposed structure | Molecular ion |
| 1. | 674,863 | 674,870 | 10,39 | GM2(d18:1/16:2) | [M-2H+]2- |
| 2. | 708,340 | 708,346 | 8,47 | GT1(d18:1/18:0) | [M-3H+]3- |
| 3. | 713,663 | 713,679 | 22,44 | GT1(t18:1/18:0) | [M-3H+]3- |
| 713,6591 | 5,47 | GT1(d18:1/16:0) | [M-5H++2Na]3- | ||
| 4. | 717,685 | 717,692 | 9,76 | GT1(d18:1/20:0) | [M-3H+]3- |
| 5. | 722,364 | 722,351 | 18,01 | GT1(t18:1/20:1) | [M-3H+]3- |
| 6. | 727,041 | 727,033 | 11,01 | GT1(d18:1/22:0) | [M-3H+]3- |
| 7. | 735,694 | 735,682 | 15,51 | (CH3COO- ) GT1(d18:1/18:0) | [M- -3H+Na]3- |
| 8. | 770,928 | 770,920 | 10,39 | GM1(d18:1/18:1) | [M-2H+]2- |
| 9. | 782,906 | 782,919 | 16,62 | GM1(d18:1/18:0) | [M-3H++Na+]2- |
| 10. | 785,932 | 785,944 | 15,29 | GM1(d18:1/20:0) | [M-2H+]2- |
| 11. | 789,952 | 789,965 | 16,48 | GD3(d18:1/26:1) | [M-2H+]2- |
| 12. | 794,012 | 794,018 | 7,56 | GQ1(d18:1/16:3) | [M-3H+]3- |
| 13. | 822,422 | 822,434 | 14,60 | GD2(d18:1/16:0) | [M-2H+]2- |
| 14. | 828,444 | 828,452 | 9,66 | GD2(d18:0/18:0) | [M-2H+]2- (-H2O) |
| 15. | 831,397 | 831,392 | 6,02 | GQ1(d18:1/22:0) | [M-3H+]3- |
| 16. | 850,481 | 850,465 | 18,82 | GD2(d18:1/20:0) | [M-2H+]2- |
| 17. | 863,462 | 863,474 | 13,90 | GD2(d18:1/22:1) | [M-2H+]2- |
| 18. | 902,122 | 902,110 | 13,30 | GP1(d18:1/18:0) | [M-3H+]3- |
| 19. | 903,468 | 903,460 | 8,86 | GD1(d18:1/16:0) | [M-2H+]2- |
| 903,479 | 12,18 | GT3(t18:0/20:0) | [M-2H+]2- | ||
| 20. | 916,460 | 916,470 | 10,92 | GD1(d18:1/18:1) | [M-2H+]2- |
| 21. | 917,463 | 917,475 | 13,09 | GD1(d18:1/18:0) | [M-2H+]2- |
| 22. | 926,463 | 926,483 | 21,60 | GD1(t18:0/18:0) | [M-2H+]2- |
| 926,453 | 10,80 | GD1(d18:1/18:2) | [M-3H++Na+]2- | ||
| 23. | 930,478 | 930,486 | 8,60 | GD1(d18:1/20:1) | [M-2H+]2- |
| 24. | 938,471 | 938,483 | 13,75 | GD1(t18:1/20:1) | [M-2H+]2- |
| 938,452 | 19,62 | GD1(d18:1/18:1) | [M-4H++2Na+]2- | ||
| 25. | 950,477 | 950,4839 | 7,26 | O-Ac-GD1(d18:1/20:2) | [M-2H+]2- |
| 950,4708 | 6,53 | O-Ac-GT3(d18:1/22:1) | [M-4H++2Na]2- | ||
| 26. | 951,493 | 951,488 | 5,26 | O-Ac-GD1(d18:1/20:1) | [M-2H+]2- |
| 27. | 958,468 | 958,476 | 8,35 | (CH3COO-) GD1(d18:1/18:0) | [M--2H++Na+]2- |
| 28. | 965,478 | 965,484 | 6,22 | (CH3COO-) GD1(d18:1/19:0) | [M--2H++Na+]2- |
| 29. | 988,486 | 988,4919 | 5,97 | FucGD1(d18:1/18:2) | [M-2H+]2- |
| 30. | 991,508 | 991,512 | 4,04 | Fuc-GT3(d18:1/24:4) | [M-2H+]2- |
| 991,502 | 6,05 | Fuc-GT3(d18:1/24:3) | [M-2H+]2- | ||
| 31. | 1003,509 | 1003,513 | 3,99 | Fuc-GD1(d18:1/20:1) | [M-2H+]2- |
| 32. | 1009,503 | 1009,512 | 8,92 | (CH3COO-) Fuc-GT3(d18:1/22:2) | [M--H+]2- |
| 1009,498 | 4,96 | (CH3COO-) GD1(d18:1/24:2) | [M--3H++2Na+]2- | ||
| 33. | 1013,486 | 1013,496 | 9,87 | Fuc-GD1(d18:1/20:2) | [M-3H++Na+]2- |
| 34. | 1018,951 | 1018,963 | 11,79 | GT1(d18:1/12:2) | [M-2H+]2- |
| 35. | 1021,973 | 1021,987 | 13,71 | GT1(d18:0/12:0) | [M-2H+]2- |
| 36. | 1024,523 | 1024,536 | 12,70 | Fuc-GD1(d18:1/23:1 | [M-2H+]2- |
| 37. | 1027,953 | 1027,969 | 15,58 | GT1(t18:1/12:1) | [M-2H+]2- |
| 38. | 1029,972 | 1029,954 | 17,49 | GT1(d18:1/12:2) | [M-3H++Na+]2- |
| 39. | 1032,963 | 1032,979 | 15,50 | GT1(d18:1/14:2) | [M-2H+]2- |
| 40. | 1033,965 | 1033,987 | 21,30 | GT1(d18:1/14:1) | [M-2H+]2- |
| 41. | 1042,984 | 1042,962 | 21,11 | GT1(d18:1/14:3) | [M-3H++Na+]2- |
| 42. | 1048,996 | 1049,010 | 13,35 | GT1(d18:1/16:0) | [M-2H+]2- |
| 43. | 1062,004 | 1062,018 | 13,18 | GT1(d18:1/18:1) | [M-2H+]2- |
| 44. | 1063,031 | 1063,026 | 4,42 | GT1(d18:1/18:0) | [M-2H+]2- |
| 45. | 1074,009 | 1074,017 | 7,45 | GT1(d18:1/20:3) | [M-2H+]2- |
| 1074,018 | 8,38 | GT1(d18:1/20:0) | [M-2H+]2- | ||
| 46. | 1077,031 | 1077,041 | 9,29 | GT1(d18:1/20:0) | [M-2H+]2- |
| 47. | 1081,997 | 1082,012 | 13,86 | O-Ac-GT1(d18:1/18:2) | [M-2H+]2- |
| 48. | 1085,022 | 1085,008 | 12,90 | GT1(d18:1/18:0) | [M-4H++2Na+]2- |
| 1085,039 | 15,67 | GT1(t18:1/20:0) | [M-2H+]2- | ||
| 49. | 1088,018 | 1088,030 | 11,03 | GT1(d18:1/20:0) | [M-3H++Na+]2- |
| 50. | 1095,982 | 1095,997 | 13,70 | GT1(d18:1/20:3) | [M-4H++2Na+]2- |
| 51. | 1099,065 | 1099,054 | 10,01 | GT1(t18:1/22:0) | [M-2H+]2- |
| 52. | 1139,658 | 1139,666 | 7,02 | GM3(t18:1/14:0) | [M-H+]- |
| 53. | 1151,724 | 1151,705 | 16,51 | GM3(d18:1/16:0) | [M-2H+]2- |
| 54. | 1209,769 | 1209,783 | 11,58 | GM3(d18:0/20:0) | [M-2H+]2- |
| 55. | 1223,583 | 1223,597 | 11,45 | GQ1(d18:0/20:0) | [M-2H+]2- |
| 56. | 1227,563 | 1227,577 | 11,41 | GQ1 (t18:1/18:0) | [M-3H++Na+]2- |
| 57. | 1310,635 | 1310,642 | 5,42 | Fuc-GQ1(d18:0/22:0) | [M-2H+]2- |
| 58. | 1382,140 | 1382,152 | 8,68 | GP1(d18:0/22:0) | [M-2H+]2- |
| 59. | 1572,873 | 1572,900 | 17,18 | GM1(d18:1/20:0) | [M-H+]- |
| 60. | 1835,978 | 1835,964 | 7,63 | GD1(d18:1/18:0) | [M-H+]- |
| 61. | 1857,961 | 1857,946 | 8,08 | GD1(d18:1/18:0) | [M-2H++Na+]- |
| 62. | 1863,974 | 1863,995 | 11,27 | GD1(d18:1/20:0) | [M-H+]- |
| 63. | 1873,961 | 1873,973 | 6,41 | GD1(d18:0/19:0) | [M-2H++Na+]- |
| 64. | 1879,913 | 1879,923 | 5,32 | GD1(d18:1/18:0) | [M-3H++2Na+] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).